Skip to main content
SpringerLink
Log in

Introduction

  • Chapter
  • First Online:
Handbook of Treatment-resistant Schizophrenia

  • 1085 Accesses

Abstract

Schizophrenia is a common chronic mental disorder estimated to have a global prevalence of about 0.5–1.0 % in the general population and a prevalence of 1.0 % in the US population [1,2]. Typically, people with schizophrenia initially present for treatment when they have their first acute psychotic episode. This usually occurs in a patient’s teens or early adulthood. Response to antipsychotic medication during the first episode is usually robust in terms of reduction of positive psychotic symptoms, such as hallucinations and delusions, and the hope is to forestall further deterioration in overall functioning.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andreasen NC, Black DW. Introductory Textbook of Psychiatry. 4th ed. Washington, DC: American Psychiatric Publishing, Inc., 2006.

    Google Scholar 

  2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR Fourth Edition (Text Revision). Arlington, VA: American Psychiatric Association; 2000.

    Google Scholar 

  3. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005;162:1785-1804.

    Google Scholar 

  4. Lieberman JA, Alvir JM, Koreen A, et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology. 1996;14(3 suppl):13S-21S.

    Google Scholar 

  5. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(suppl 4):1-46.

    Google Scholar 

  6. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.

    Google Scholar 

  7. Kane JM, Marder SR, Schooler NR, et al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry. 2001;58:965-972.

    Google Scholar 

  8. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 2002;159:255-262.

    Google Scholar 

  9. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.

    Google Scholar 

  10. McEvoy JP, Lieberman JA, Stroup TS, et al; CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163:600-610.

    Google Scholar 

  11. Kurtz MM. Symptoms versus neurocognitive skills as correlates of everyday functioning in severe mental illness. Expert Rev Neurother. 2006;6:47-56.

    Google Scholar 

  12. Rush AJ Jr., First MB, Blacker D, eds. Handbook of Psychiatric Measures. 2nd ed. Arlington, VA: American Psychiatric Publishing, Inc; 2008.

    Google Scholar 

  13. Lindenmayer JP, Czobor P, Volavka J, et al. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. J Clin Psychiatry. 2004;65:551-556.

    Google Scholar 

  14. Lehoux C, Gobeil MH, Lefebvre AA, Maziade M, Roy MA. The five-factor structure of the PANSS: a critical review of its consistency across studies. Clin Schizophr Relat Psychoses. 2009;3:103-110.

    Google Scholar 

  15. Citrome L, Bilder RM, Volavka J. Managing treatment-resistant schizophrenia: evidence from randomized clinical trials. J Psychiatr Pract. 2002;8:205-215.

    Google Scholar 

  16. Volavka J, Citrome L. Heterogeneity of violence in schizophrenia and implications for long-term treatment. Int J Clin Pract. 2008;62:1237-1245.

    Google Scholar 

  17. Opler LA, Ramirez PM. Use of the positive and negative syndrome scale (PANSS) in clinical practice. J Practical Psychiatry Behavior Health. 1998;4:157-62.

    Google Scholar 

  18. Opler LA, Opler MG, Malaspina D. Reducing guesswork in schizophrenia treatment. Curr Psychiatry. 2006;5:76-78, 81-82, 84.

    Google Scholar 

  19. Guy W. ECDEU Assessment Manual for Psychopharmacology Revised, 1976. Rockville, MD: US D epartment of Health, Education, and Welfare, National Institute of Mental Health; 1976. DHEW publication (ADM) 76-338.

    Google Scholar 

  20. Levine SZ, Rabinowitz J, Engel R, Etschel E, Leucht S. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr Res. 2008;98:318-322.

    Google Scholar 

  21. Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology. 2006;31:2318-2325.

    Google Scholar 

  22. Haro JM, Kamath SA, Ochoa S, et al; SOHO Study Group. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003;(416):16-23.

    Google Scholar 

  23. Targum SD, Pestreich L, Reksoprodjo P, Pereira H, Guindon C, Hochfeld M. A global measure to assess switching antipsychotic medications in the treatment of schizophrenia. Hum Psychopharmacol. 2012;27:455-463.

    Google Scholar 

  24. Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165:203-213.

    Google Scholar 

  25. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.

    Google Scholar 

  26. Figueira ML, Brissos S. Measuring psychosocial outcomes in schizophrenia patients. Curr Opin Psychiatry. 2011;24:91-99.

    Google Scholar 

  27. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM -IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101:323-329.

    Google Scholar 

  28. Nafees B, van Hanswijck de Jonge P, Stull D, et al. Reliability and validity of the Personal and Social Performance scale in patients with schizophrenia. Schizophr Res. 2012;140:71-76.

    Google Scholar 

  29. Patterson TL, Goldman S, McKibbin CL, Hughs T, Jeste DV. UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull. 2001;27:235-245.

    Google Scholar 

  30. Invega® (paliperidone) [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2011.

    Google Scholar 

  31. Harvey PD, Bowie CR. Cognitive enhancement in schizophrenia: pharmacological and cognitive remediation approaches. Psychiatr Clin North Am. 2012;35:683-698.

    Google Scholar 

  32. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441-449.

    Google Scholar 

  33. Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study. Schizophr Res. 2011;133:42-46.

    Google Scholar 

  34. Harvey PD, Bellack AS. Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept? Schizophr Bull. 2009;35:300-306.

    Google Scholar 

  35. Peebles SA, Mabe PA, Davidson L, Fricks L, Buckley PF, Fenley G. Recovery and systems transformation for schizophrenia. Psychiatr Clin North Am. 2007;30:567-583.

    Google Scholar 

  36. Liberman RP, Kopelowicz A. Recovery from schizophrenia: a concept in search of research. Psychiatr Serv. 2005;56:735-742.

    Google Scholar 

  37. Liberman RP, Kopelowicz A, Ventura J, Gutkind D. Operational criteria and factors related to recovery from schizophrenia. Int Rev Psychiatry. 2002;14:256-272.

    Google Scholar 

  38. Davidson L, Schmutte T, Dinzeo T, Andres-Hyman R. Remission and recovery in schizophrenia: practitioner and patient perspectives. Schizophr Bull. 2008;34:5-8.

    Google Scholar 

  39. Davidson L, O’Connell MJ, Tondora J, Lawless M, Evans AC. Recovery in serious mental illness: a new wine or just a new bottle? Prof Psychol Res Pr. 2005;36:480-487.

    Google Scholar 

  40. US Department of Health and Human Services Substance Abuse and Mental Health Services Administration Center for Mental Health Services. National consensus statement on mental health recovery. www.store.samhsa.gov/shin/

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA

    Leslie Citrome

Authors
  1. Leslie Citrome
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leslie Citrome .

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Healthcare

About this chapter

Cite this chapter

Citrome, L. (2013). Introduction. In: Handbook of Treatment-resistant Schizophrenia. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-908517-88-3_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-908517-88-3_1

  • Published:

  • Publisher Name: Springer Healthcare, Tarporley

  • Print ISBN: 978-1-908517-86-9

  • Online ISBN: 978-1-908517-88-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation